Therapeutic Plasma Exchange for the Treatment of Rapidly Progressive Glomerulonephritis
Version of Record online: 14 NOV 2007
Volume 1, Issue 3, pages 255–259, August 1997
How to Cite
Kaplan, A. A. (1997), Therapeutic Plasma Exchange for the Treatment of Rapidly Progressive Glomerulonephritis. Therapeutic Apheresis, 1: 255–259. doi: 10.1111/j.1744-9987.1997.tb00148.x
- Issue online: 14 NOV 2007
- Version of Record online: 14 NOV 2007
- Received March 1997.
- Rapidly progressing glomerulonephritis;
- Renal failure;
- Plasma exchange;
- Antineutrophil cytoplasmic antibody
Abstract: Therapeutic plasma exchange (TPE) has been widely accepted as a successful means of removing the antiglomerular basement membrane (anti-GBM) antibodies that result in the rapidly progressive glomerulonephritis (RPGN) of Goodpasture's syndrome. TPE has also been investigated as a means of removing the immune complexes associated with the glomerulonephritides of systemic lupus erythematosus, IgA nephropathy, Henoch Schönlein purpura, and cryoglobulinemia. Recently, an antineutrophil cytoplasmic antibody (ANCA) has been implicated in the pathogenesis of RPGN associated with such diseases such as Wegener's granulomatosis and periarteritis nodosa. ANCA has also been found in many cases of RPGN formally considered to be idiopathic. The identification of this autoantibody has given new credence to the possibility that TPE may be beneficial in the treatment of these diseases. This article reviews the data regarding the use of TPE for RPGN.